You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Microcapillary Quartz Sensors for Screening Injectability of High Concentration Protein Formulations
SBC: QATCH TECHNOLOGIES LLC Topic: NoneThe objective of this SBIR Phase I proposal is to determine the feasibility of viscosity characterization of high concentration protein formulations (HCF) by QATCH’s microcapillary quartz technology. HCFs are non-Newtonian fluids with shear-thinning behavior and they are administered to patients by subcutaneous or muscular injections. The injectability of HCFs depends on the viscosity at high-sh ...
SBIR Phase I 2019 Department of CommerceNational Institute of Standards and Technology -
TOPIC 382- INTEGRATED IMAGING AND MOLECULAR ANALYSIS OF GLIOBLASTOMA USING SCOPE SEQ ON THE AIR FLOW
SBC: CELL MICROSYSTEMS INC Topic: NCICombining both genomic analysis and highEresolution imaging on a cellEbyEcell basis typically relies on customized technology which often requires significant expertise and capital costCell MicrosystemsInchas partnered with Peter SimsPhD of Columbia University to commercialize a novel workflow for integrated imaging and sample preparation for single cell transcriptomic analysisDrSims workflowSingl ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
An integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings.
SBC: CERTIRX CORPORATION Topic: NIDAUnder the Small Business Innovation Research ProgramSBIRPhase I programTopicthe Contractor will develop an integrated device and system for drug detection and deactivation to deter controlled substance theft in hospitals and other healthcare delivery settings
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain
SBC: NeuroCycle Therapeutics, Inc. Topic: NIAMSPROJECT SUMMARY Non steroidal anti inflammatory drugsNSAIDsare a first line pharmacologic pain therapy for chronic musculoskeletal painand rheumatoid arthritisRAand moderate to severe osteoarthritisOAspecificallyHoweverinsufficient pain relief by NSAID monotherapy has encouraged the use of combination therapyCombinations of NSAIDs plus weak opioids are widely used although objective evidence for e ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding
SBC: Dignify Therapeutics LLC Topic: 105PROJECT SUMMARYABSTRACTSpinal cord injurySCIaffects an estimatedAmericansDamage to nerves in the spinal cord can result in a loss of voluntary control over bladder and bowel function that often produces both incontinence and retention of urine and stools in the same patientThe standard of care for urine retention is bladder catheterization to void urinewhich may produce urinary tract infectionsUTI ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain
SBC: AFFINERGY, LLC Topic: NIDASUMMARY ABSTRACT Chronicnon cancer pain is a significant unmet health need worldwideThe prevalence of chronic pain among adults in the United States has been estimated at betweenandThe personal toll of living with chronic pain is immenseand the economic impact can be devastatingOne of the most widely used treatments for chronic pain is opioid analgesicsWhile the appropriate use of opioids can be a ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds
SBC: Initos Pharmaceuticals LLC Topic: NCATSABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing novel inhibitors of the gut microbiome to modulate drug metabolism
SBC: SYMBERIX, INC. Topic: 100The long term objective of this project is a therapeutic adjunct to prevent adverse gastrointestinal eventsincluding life threatening diarrheaassociated with Ofevand Stivargaused to treat idiopathic pulmonary fibrosis and metastatic colorectal cancerrespectivelyAdverse GI events associated with both drugs is a major reason for reducingpostponingor stopping treatmentthus compromising efficacyOne fu ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen
SBC: Arrevus, Inc. Topic: NIAIDMulti drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies
SBC: Alterna Therapeutics, Inc. Topic: NHLBIABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health